Referral: Havrix, hepatitis A virus (inactivated, adsorbed), associated names: Havrix and associated names Article 30 referrals European Commission final decision, 27/06/2024, 26/08/2024, 04/09/2024

Referral: Havrix, hepatitis A virus (inactivated, adsorbed), associated names: Havrix and associated names Article 30 referrals European Commission final decision, 27/06/2024, 26/08/2024, 04/09/2024

Sponsor's report on the maintenance of the designation criteria at the time of marketing authorisation for a designated orphan-medicinal-product

Sponsor's report on the maintenance of the designation criteria at the time of marketing authorisation for a designated orphan-medicinal-product

Human medicines European public assessment report (EPAR): Fabrazyme, agalsidase beta, Date of authorisation: 03/08/2001, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR): Fabrazyme, agalsidase beta, Date of authorisation: 03/08/2001, Revision: 37, Status: Authorised

Clinical Trials Information System (CTIS): Information day, Online, European Medicines Agency, Amsterdam, the Netherlands, from 17 October 2024, 13:30 (CEST) to 17 October 2024, 17:30 (CEST)

Clinical Trials Information System (CTIS): Information day, Online, European Medicines Agency, Amsterdam, the Netherlands, from 17 October 2024, 13:30 (CEST) to 17 October 2024, 17:30 (CEST)

Human medicines European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius), carmustine, Date of authorisation: 18/07/2018, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius), carmustine, Date of authorisation: 18/07/2018, Revision: 11, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.